IP Library Granted Patent US 9,861,670
Granted Patent B2
US 9,861,670 · App. 14/773,127 · Granted Jan 9, 2018

Stabilized cream formulations comprising sandalwood oil

Inventors: Ian Clements (San Antonio, TX); Paul Castella (San Antonio, TX); Corey Levenson (San Antonio, TX)
Assignee: SANTALIS HEALTHCARE CORPORATION
A61K36/185A61K9/0014A61K9/06A61K31/05A61K31/122A61K36/53A61K45/06A61K9/107
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,861,670
App. No.
14/773,127
Granted
Jan 9, 2018
Kind
B2
Abstract

Provided herein are cream formulations comprising sandalwood oil, an antioxidant and a phosphate buffer. Also provided are methods of making and using the formulations. Further provided herein is a method of treating a skin disorder in a subject by administering to the subject a therapeutically effective amount of a cream formulation comprising sandalwood oil, an antioxidant and a phosphate buffer, wherein the subject has a skin disorder or is at risk of developing a skin disorder.

Claims (18)

1. A stabilized cream formulation for treating a skin disorder comprising effective amounts of:

a) Sandalwood oil;

b) one or more antioxidants; and

c) a phosphate buffer,

wherein the concentration of the one or more antioxidants is from about 0.03% (w/w) to about 0.5% (w/w), wherein the pH of the formulation is between about 4 and about 6; and wherein the one or more antioxidants are selected from the group consisting of t-butyl hydroquinone (TBHQ) and rosemary extract.

2. The formulation of claim 1 , wherein the sandalwood oil is from Santalum album or Santalum spicatum or a combination thereof.

3. The formulation of claim 1 , wherein the concentration of the sandalwood oil is from about 0.3% (w/w) to about 10% (w/w).

4. The formulation of claim 1 , wherein the concentration of the one or more antioxidants is from about 0.05% (w/w) to about 0.1% (w/w).

5. The formulation of claim 1 , wherein the phosphate buffer is monobasic potassium phosphate buffer or dibasic potassium phosphate buffer.

6. The formulation of claim 1 , wherein the concentration of the phosphate buffer is from about 0.4% (w/w) to about 10% (w/w).

7. The formulation of claim 1 , wherein the formulation further comprises a solvent.

8. The formulation of claim 7 , wherein the solvent is water.

9. The formulation of claim 1 , wherein the formulation further comprises one or more pharmaceutically acceptable excipients.

10. A method of treating a skin disorder in a subject comprising administering a therapeutically effective amount of a formulation of claim 1 to the subject, wherein the subject has a skin disorder or is at risk of developing a skin disorder wherein the skin disorder is selected from the group consisting of acne, psoriasis, eczema, dermatitis, fungal infection, actinic keratosis, diaper rash, Molluscum contagiosum and impetigo.

11. The method of claim 10 , wherein the formulation is administered topically.

12. The formulation of claim 1 , wherein the sandalwood oil does not comprise an ester derivative of santalol.

13. The formulation of claim 12 , wherein the santalol is an alpha-santalol.

14. The formulation of claim 12 , wherein the santalol is a beta-santalol.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Oct 23, 2018
From: BTA INSTITUTIONAL SERVICES AUSTRALIA LIMITED
To: SANTALIS HEALTHCARE CORPORATION; SANTALIS PHARMACEUTICALS, INC.
Reel/Frame 047282/0428 →
SECURITY INTEREST Recorded Oct 23, 2018
From: SANTALIS HEALTHCARE CORPORATION; SANTALIS PHARMACEUTICALS, INC.
To: GLOBAL LOAN AGENCY SERVICES AUSTRALIA NOMINEES PTY LTD
Reel/Frame 047282/0532 →
PATENT SECURITY AGREEMENT Recorded Aug 1, 2016
From: SANTALIS PHARMACEUTICALS, INC.; SANTALIS HEALTHCARE CORPORATION
To: BTA INSTITUTIONAL SERVICES AUSTRALIA LIMITED
Reel/Frame 039535/0701 →
MERGER AND CHANGE OF NAME Recorded Jul 7, 2016
From: VIROXIS CORPORATION; VIROXIS CORPORATION
To: SANTALIS HEALTHCARE CORPORATION
Reel/Frame 039100/0336 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 13, 2015
From: CLEMENTS, IAN; CASTELLA, PAUL; LEVENSON, COREY
To: VIROXIS CORPORATION
Reel/Frame 037031/0505 →
Continuity (2)
Provisional Application 61780038 · Mar 13, 2013
Related Publication 20160008415A1 · Jan 14, 2016